CORRECTION article

Front. Immunol., 22 April 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1606194

Corrigendum: Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs

This article is a correction to:

  1. Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs

    1. Read original article
Shengwen Shao&#x;Shengwen Shao1†Huilai Miao,&#x;Huilai Miao2,3†Wenxue Ma*Wenxue Ma4*
  • 1Clinical Research Center, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
  • 2Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
  • 3Department of Hepatobiliary Surgery, Liaobu Hospital of Dongguan City, Dongguan, Guangdong, China
  • 4Department of Medicine, Moores Cancer Center, and Sanford Stem Cell Institute, University of California, San Diego, La Jolla, CA, United States

A Corrigendum on
Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs

By Shao S, Miao H and Ma W (2023). Front. Immunol. 14:1295684. doi: 10.3389/fimmu.2023.1295684

In the published article, there was an error. The labels for M1 and M2 macrophage subtypes were mistakenly reversed due to an oversight by the authors.

A correction has been made to Section 2. The multifaced role of TAMs in the TME, Paragraph 1. This sentence previously stated: “TAMs possess the ability to transition between pro-tumor (M1) and anti- tumor (M2) roles.”

The corrected sentence appears below: “TAMs possess the ability to transition between pro-tumor (M2) and anti-tumor (M1) roles.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: tumor-associated macrophages (TAM), tumor microenvironment (TME), phenotypic diversity, regulatory signaling pathways, clinical trials, cancer immunotherapy

Citation: Shao S, Miao H and Ma W (2025) Corrigendum: Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs. Front. Immunol. 16:1606194. doi: 10.3389/fimmu.2025.1606194

Received: 04 April 2025; Accepted: 07 April 2025;
Published: 22 April 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Shao, Miao and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Wenxue Ma, d21hQGhlYWx0aC51Y3NkLmVkdQ==

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.